Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

1.

Immune monitoring technology primer: the enzyme-linked immunospot (Elispot) and Fluorospot assay.

Janetzki S.

J Immunother Cancer. 2015 Jul 21;3:30. doi: 10.1186/s40425-015-0074-0. eCollection 2015. No abstract available.

2.

Guidelines for the automated evaluation of Elispot assays.

Janetzki S, Price L, Schroeder H, Britten CM, Welters MJ, Hoos A.

Nat Protoc. 2015 Jul;10(7):1098-115. doi: 10.1038/nprot.2015.068. Epub 2015 Jun 25.

PMID:
26110715
3.

Correction: Santos, R.S., et al. Improvement of IFNγ ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis. Cells 2015, 4, 1-18.

Santos R, Buying A, Sabri N, Yu J, Gringeri A, Bender J, Janetzki S, Pinilla C, Judkowski VA.

Cells. 2015 Apr 21;4(2):133-4. doi: 10.3390/cells4020133.

4.

Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis.

Santos R, Buying A, Sabri N, Yu J, Gringeri A, Bender J, Janetzki S, Pinilla C, Judkowski VA.

Cells. 2014 Dec 24;4(1):1-18. doi: 10.3390/cells4010001. Erratum in: Cells. 2015;4(2):133-4.

5.

Stepping up ELISpot: Multi-Level Analysis in FluoroSpot Assays.

Janetzki S, Rueger M, Dillenbeck T.

Cells. 2014 Nov 27;3(4):1102-15. doi: 10.3390/cells3041102.

6.

The role of the reporting framework MIATA within current efforts to advance immune monitoring.

Janetzki S, Britten CM; MIATA Core Team.

J Immunol Methods. 2014 Jul;409:6-8. doi: 10.1016/j.jim.2014.05.003. Epub 2014 May 9. No abstract available.

PMID:
24816466
7.

Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells.

Patton K, Aslam S, Lin J, Yu L, Lambert S, Dawes G, Esser MT, Woo J, Janetzki S, Cherukuri A.

Clin Vaccine Immunol. 2014 May;21(5):628-35. doi: 10.1128/CVI.00736-13. Epub 2014 Feb 26.

8.

Immunological Monitoring to Rationally Guide AAV Gene Therapy.

Britten CM, Walter S, Janetzki S.

Front Immunol. 2013 Sep 12;4:273. doi: 10.3389/fimmu.2013.00273. Review.

9.

Structured reporting of T cell assay results.

Janetzki S, Hoos A, Melief CJ, Odunsi K, Romero P, Britten CM.

Cancer Immun. 2013 Jul 15;13:13. Print 2013. No abstract available.

10.

A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI).

McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S.

Cytometry A. 2013 Aug;83(8):728-38. doi: 10.1002/cyto.a.22319. Epub 2013 Jun 20.

11.
12.

Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.

Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, Welters MJ, Ottensmeier C, van der Burg SH, Gouttefangeas C, Britten CM.

Cancer Immunol Immunother. 2013 Apr;62(4):615-27. doi: 10.1007/s00262-012-1359-5. Epub 2012 Nov 9.

13.

T cell assays and MIATA: the essential minimum for maximum impact.

Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM.

Immunity. 2012 Jul 27;37(1):1-2. doi: 10.1016/j.immuni.2012.07.010. No abstract available.

14.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

15.

Harmonization of immune biomarker assays for clinical studies.

van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A.

Sci Transl Med. 2011 Nov 9;3(108):108ps44. doi: 10.1126/scitranslmed.3002785. Review.

PMID:
22072636
16.

Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.

Moodie Z, Price L, Janetzki S, Britten CM.

Methods Mol Biol. 2012;792:185-96. doi: 10.1007/978-1-61779-325-7_15.

PMID:
21956511
17.

The impact of harmonization on ELISPOT assay performance.

Janetzki S, Britten CM.

Methods Mol Biol. 2012;792:25-36. doi: 10.1007/978-1-61779-325-7_2.

PMID:
21956498
18.

A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols.

Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM; CRI-CIC Assay Working Group.

J Transl Med. 2011 Jul 11;9:108. doi: 10.1186/1479-5876-9-108.

19.

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML.

Clin Cancer Res. 2011 May 15;17(10):3064-76. doi: 10.1158/1078-0432.CCR-10-2234. Epub 2011 May 10. Review.

20.

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.

Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM.

Cancer Immunol Immunother. 2011 Jan;60(1):15-22. doi: 10.1007/s00262-010-0940-z. Epub 2010 Nov 16.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk